Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 11/30
| 08-2023 | 05-2023 | 02-2023 | 11-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -101,992 | -65,010 | -40,733 | -180,360 | N/A |
| Depreciation Amortization | 6,444 | 4,705 | 2,362 | 11,234 | N/A |
| Accounts receivable | -2,000 | N/A | N/A | 6,000 | N/A |
| Accounts payable and accrued liabilities | -3,036 | -1,839 | 400 | 85 | N/A |
| Other Working Capital | -38,699 | -23,916 | -18,618 | -19,022 | N/A |
| Other Operating Activity | 31,229 | 19,139 | 8,137 | 22,256 | 0 |
| Operating Cash Flow | $-108,054 | $-66,921 | $-48,452 | $-159,807 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5,816 | -3,357 | -2,277 | -12,244 | N/A |
| Purchase Of Investment | -157,941 | -83,353 | -22,642 | -239,366 | N/A |
| Sale Of Investment | 246,431 | 146,609 | 40,987 | 278,808 | N/A |
| Investing Cash Flow | $82,674 | $59,899 | $16,068 | $27,198 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 3,210 | 1,506 | 1,481 | 22,433 | N/A |
| Other Financing Activity | 0 | 0 | 0 | 94,759 | 0 |
| Financing Cash Flow | $3,210 | $1,506 | $1,481 | $117,192 | $N/A |
| Beginning Cash Position | 65,375 | 65,375 | 65,375 | 80,792 | N/A |
| End Cash Position | 43,205 | 59,859 | 34,472 | 65,375 | N/A |
| Net Cash Flow | $-22,170 | $-5,516 | $-30,903 | $-15,417 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -108,054 | -66,921 | -48,452 | -159,807 | N/A |
| Capital Expenditure | -5,816 | -3,357 | -2,277 | -12,244 | N/A |
| Free Cash Flow | -113,870 | -70,278 | -50,729 | -172,051 | 0 |